154 related articles for article (PubMed ID: 38612725)
21. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
Sugianto J; Sarode V; Peng Y
Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
[TBL] [Abstract][Full Text] [Related]
22. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
23. The value of potential immunohistochemical biomarkers and clinicopathological findings in predicting response to neoadjuvant chemotherapy in breast cancer.
Akay E; Eren SK; Özhan N; Arslan A; Karaman H
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7070-7083. PubMed ID: 36263555
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract][Full Text] [Related]
25. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer.
Zhu X; Chen L; Huang B; Wang Y; Ji L; Wu J; Di G; Liu G; Yu K; Shao Z; Wang Z
Sci Rep; 2020 Jan; 10(1):225. PubMed ID: 31937819
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the Predictive Role of Serum Lipid Profiles in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Qu F; Chen R; Peng Y; Ye Y; Tang Z; Wang Y; Zong B; Yu H; Liu S
J Breast Cancer; 2020 Jun; 23(3):246-258. PubMed ID: 32595987
[TBL] [Abstract][Full Text] [Related]
27. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
28. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
31. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
Shokouh TZ; Ezatollah A; Barand P
Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
[TBL] [Abstract][Full Text] [Related]
32. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
33. Predictive Significance of Ki-67 and Platelet Lymphocyte Ratio in Patients with Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy.
Yilmaz H; Demirag G; Sullu Y; Yilmaz A
J Coll Physicians Surg Pak; 2021 May; 31(5):546-552. PubMed ID: 34027867
[TBL] [Abstract][Full Text] [Related]
34. Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.
Gandini S; Guerrieri-Gonzaga A; Pruneri G; Serrano D; Cazzaniga M; Lazzeroni M; Veronesi P; Johansson H; Bonanni B; Viale G; DeCensi A
Ann Oncol; 2014 Mar; 25(3):618-623. PubMed ID: 24351403
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes].
Liu Y; Zhang X; Yu F; Liu J; Zhang M; Zhang S; Hao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):671-6. PubMed ID: 25564057
[TBL] [Abstract][Full Text] [Related]
38. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
Goetz MP; Kalari KR; Suman VJ; Moyer AM; Yu J; Visscher DW; Dockter TJ; Vedell PT; Sinnwell JP; Tang X; Thompson KJ; McLaughlin SA; Moreno-Aspitia A; Copland JA; Northfelt DW; Gray RJ; Hunt K; Conners A; Sicotte H; Eckel-Passow JE; Kocher JP; Ingle JN; Ellingson MS; McDonough M; Wieben ED; Weinshilboum R; Wang L; Boughey JC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376176
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
40. Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy.
Goto W; Kashiwagi S; Takada K; Asano Y; Ogisawa K; Morisaki T; Shibutani M; Tanaka H; Maeda K
Eur J Med Res; 2023 Jan; 28(1):2. PubMed ID: 36593486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]